JP2012506911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506911A5 JP2012506911A5 JP2011534697A JP2011534697A JP2012506911A5 JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5 JP 2011534697 A JP2011534697 A JP 2011534697A JP 2011534697 A JP2011534697 A JP 2011534697A JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- release formulation
- diacerein
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 238000009472 formulation Methods 0.000 claims 33
- 238000013270 controlled release Methods 0.000 claims 22
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 15
- 229960004590 diacerein Drugs 0.000 claims 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10893108P | 2008-10-28 | 2008-10-28 | |
| US61/108,931 | 2008-10-28 | ||
| PCT/US2009/062302 WO2010051296A1 (en) | 2008-10-28 | 2009-10-28 | Pharmaceutical compositions containing diacerein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506911A JP2012506911A (ja) | 2012-03-22 |
| JP2012506911A5 true JP2012506911A5 (enExample) | 2012-12-06 |
| JP5642691B2 JP5642691B2 (ja) | 2014-12-17 |
Family
ID=42117735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534697A Expired - Fee Related JP5642691B2 (ja) | 2008-10-28 | 2009-10-28 | ジアセレインを含有する医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100104651A1 (enExample) |
| EP (1) | EP2349289B1 (enExample) |
| JP (1) | JP5642691B2 (enExample) |
| KR (1) | KR101718347B1 (enExample) |
| CN (1) | CN102202673B (enExample) |
| AR (1) | AR073918A1 (enExample) |
| AU (1) | AU2009308958B2 (enExample) |
| BR (1) | BRPI0920255A2 (enExample) |
| CA (1) | CA2741846C (enExample) |
| ES (1) | ES2585904T3 (enExample) |
| IL (1) | IL212483A (enExample) |
| MX (1) | MX2011004395A (enExample) |
| NZ (1) | NZ592376A (enExample) |
| PA (1) | PA8846801A1 (enExample) |
| RU (1) | RU2542461C2 (enExample) |
| SA (1) | SA109300644B1 (enExample) |
| TW (1) | TWI473610B (enExample) |
| UY (1) | UY32204A (enExample) |
| WO (1) | WO2010051296A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012024936A2 (pt) * | 2010-04-08 | 2015-09-15 | Twi Biotechnology Inc | uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo |
| CN101822660B (zh) * | 2010-05-13 | 2013-07-10 | 中国人民解放军肾脏病研究所 | 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用 |
| RU2603050C2 (ru) * | 2011-03-11 | 2016-11-20 | ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК. | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией |
| CN102743370B (zh) * | 2011-06-27 | 2013-05-15 | 王子厚 | 双醋瑞因的用途 |
| US9757424B2 (en) | 2011-09-27 | 2017-09-12 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
| WO2013100881A2 (en) * | 2011-12-27 | 2013-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
| WO2013100882A2 (en) * | 2011-12-27 | 2013-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combinations of diacerein and non-steroidal inflammation drugs |
| CN102871982B (zh) * | 2012-10-16 | 2014-09-10 | 中国科学院上海药物研究所 | 一种药物渗透泵制剂 |
| US11198724B2 (en) * | 2013-03-14 | 2021-12-14 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| CA2983394A1 (en) * | 2015-04-20 | 2016-10-27 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
| US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
| JP7577428B2 (ja) * | 2015-07-01 | 2024-11-05 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | ジアセレインまたはレインの局所製剤およびその使用 |
| JP6887987B2 (ja) * | 2015-08-17 | 2021-06-16 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ |
| BR112019014761A2 (pt) * | 2017-01-18 | 2020-03-03 | Tairx, Inc. | Composições para uso no tratamento de doenças inflamatórias do intestino e da colite intestinal |
| EP3570835B1 (en) * | 2017-01-19 | 2023-08-09 | TWI Biotechnology, Inc. | Diacerein for preventing or treating immunoinflammatory dermal disorders |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| CN107929264B (zh) * | 2017-12-04 | 2020-04-24 | 广东药科大学 | 双醋瑞因缓释微球及其制备方法 |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| SG11202105025VA (en) | 2018-11-14 | 2021-06-29 | Zhuhai Qiwei Bio Tech Ltd | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| CN113440503B (zh) * | 2021-07-02 | 2022-03-18 | 温州医科大学附属口腔医院 | 超长效可控缓释介孔-透明质酸杂化靶向抗菌纳米材料及其制备方法、用途 |
| CN115227664A (zh) * | 2022-06-27 | 2022-10-25 | 苏州中化药品工业有限公司 | 一种双醋瑞因胶囊及其制备方法与应用 |
| CN120981225A (zh) * | 2023-03-28 | 2025-11-18 | 蒂洛特斯制药股份有限公司 | 用于在下部胃肠道中缓释的包含抗体的固体口服剂型 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA761627B (en) * | 1976-03-16 | 1978-01-25 | C Friedmann | Improvements in or relating to the treatment of arthritis |
| US5225192A (en) * | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| US5569469A (en) * | 1984-10-16 | 1996-10-29 | Vectorpharma International, S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| IT1197316B (it) * | 1986-10-01 | 1988-11-30 | Proter Spa | Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico |
| IT1230566B (it) * | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5840881A (en) * | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| ATE183641T1 (de) * | 1992-12-23 | 1999-09-15 | Saitec Srl | Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen |
| FR2757397B1 (fr) * | 1996-12-23 | 1999-03-05 | Mazal Pharma | Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree |
| US6197818B1 (en) * | 1998-09-01 | 2001-03-06 | Nanjing General Hospital Of Nanjing Command, Pla | Drug for treating diabetic nephrosis |
| HUP0401640A2 (hu) * | 2001-08-25 | 2004-12-28 | Arakis Ltd. | Antrokinonok alkalmazása vesebetegségek kezelésére alkalmas gyógyszerkészítmények előállítására |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| MXPA05001707A (es) * | 2002-08-30 | 2005-04-19 | Pharmacia Corp | Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,. |
| AU2003230189A1 (en) * | 2003-01-29 | 2004-08-23 | Nitin Bhalachandra Dharmadhikari | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| CN1748675A (zh) * | 2005-07-11 | 2006-03-22 | 丛晓东 | 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN100475201C (zh) * | 2007-03-19 | 2009-04-08 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸缓释片的制备方法 |
| CA2709236A1 (en) * | 2007-09-27 | 2009-04-02 | Wockhardt Research Centre | Pharmaceutical compositions of rhein or diacerein |
| WO2009048940A2 (en) * | 2007-10-08 | 2009-04-16 | Dr. Reddy's Laboratories Ltd. | Diacerein pharmaceutical formulations |
-
2009
- 2009-10-07 TW TW98134006A patent/TWI473610B/zh not_active IP Right Cessation
- 2009-10-22 AR ARP090104059A patent/AR073918A1/es not_active Application Discontinuation
- 2009-10-27 SA SA109300644A patent/SA109300644B1/ar unknown
- 2009-10-28 CN CN2009801431098A patent/CN102202673B/zh not_active Expired - Fee Related
- 2009-10-28 EP EP09824084.9A patent/EP2349289B1/en not_active Not-in-force
- 2009-10-28 NZ NZ592376A patent/NZ592376A/xx not_active IP Right Cessation
- 2009-10-28 MX MX2011004395A patent/MX2011004395A/es active IP Right Grant
- 2009-10-28 BR BRPI0920255A patent/BRPI0920255A2/pt not_active IP Right Cessation
- 2009-10-28 AU AU2009308958A patent/AU2009308958B2/en not_active Ceased
- 2009-10-28 PA PA20098846801A patent/PA8846801A1/es unknown
- 2009-10-28 WO PCT/US2009/062302 patent/WO2010051296A1/en not_active Ceased
- 2009-10-28 JP JP2011534697A patent/JP5642691B2/ja not_active Expired - Fee Related
- 2009-10-28 UY UY0001032204A patent/UY32204A/es not_active Application Discontinuation
- 2009-10-28 CA CA2741846A patent/CA2741846C/en not_active Expired - Fee Related
- 2009-10-28 ES ES09824084.9T patent/ES2585904T3/es active Active
- 2009-10-28 RU RU2011121609/15A patent/RU2542461C2/ru not_active IP Right Cessation
- 2009-10-28 KR KR1020117012172A patent/KR101718347B1/ko not_active Expired - Fee Related
- 2009-10-28 US US12/607,251 patent/US20100104651A1/en not_active Abandoned
-
2011
- 2011-04-26 IL IL212483A patent/IL212483A/en active IP Right Grant
-
2013
- 2013-02-15 US US13/768,844 patent/US20130156857A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506911A5 (enExample) | ||
| RU2011121609A (ru) | Фармацевтические композиции, содержащие диацереин | |
| KR101241624B1 (ko) | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 | |
| CA2332790C (en) | Controlled release lipoic acid | |
| TWI538700B (zh) | 伊伐佈雷定或其可藥用鹽的緩釋製劑 | |
| US9446032B2 (en) | Methods for treating cardiovascular disorders | |
| JP2013522373A5 (enExample) | ||
| JP2010501607A5 (enExample) | ||
| TW200418453A (en) | Modified release pharmaceutical compositions | |
| JP2007506774A5 (enExample) | ||
| CA2642851A1 (en) | Low flush niacin formulation | |
| JP2010527347A5 (enExample) | ||
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| AU2012290987B2 (en) | Left ventricular diastolic function improving agent | |
| TW201035089A (en) | Pharmaceutical composition | |
| CN106983726B (zh) | 阿齐沙坦片及其制备方法 | |
| WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| JP2007529564A5 (enExample) | ||
| CN101642443B (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| RU2014146936A (ru) | Композиции с немедленным высвобождением лекарственного средства | |
| WO2007019540A2 (en) | Controlled release alpha-lipoic acid formulation with an inositol compound | |
| CA2946158A1 (en) | Pharmaceutical composition with anti-inflammatory agents and production process | |
| US20230022200A1 (en) | Drug that prevents dialysis shift or renal death |